DKSH has sold its healthcare business in China to Warburg Pincus. The price of the acquisition was about $100 million.
Zurich, Switzerland, November 1, 2018 – DKSH, the leading Market Expansion Services provider with a focus on Asia, today announced the successful transfer of its healthcare business in China. The company had pursued a niche strategy in the Chinese healthcare market for many years. DKSH, in accordance with its increased strategic focus and in the context of a recent portfolio review, identified Warburg Pincus as the ideal new owner. Warburg Pincus’ scale and experience will allow them to further take advantage of the potential in the business.
Since the announcement of the sale in July, DKSH has fulfilled all necessary closing conditions and has obtained the relevant regulatory approvals to complete the transaction per October 31, 2018. The transaction includes DKSH’s pharma, consumer health and medical device businesses in China. DKSH continues to be present in China with its Business Units Consumer Goods, Performance Materials and Technology.
The purchase price is approximately CHF 100 million, and last year’s net sales related to the transaction amounted to around CHF 300 million. DKSH will deconsolidate the business starting from November.
About DKSH Group
DKSH is the leading Market Expansion Services provider with a focus on Asia. As the term “Market Expansion Services” suggests, DKSH helps other companies and brands to grow their business in new or existing markets. Publicly listed on the SIX Swiss Exchange since 2012, DKSH is a global company headquartered in Zurich. With 825 business locations in 37 markets – 800 of them in Asia – and 31,970 specialized staff, DKSH generated net sales of CHF 11.0 billion in 2017. DKSH was founded in 1865. With strong Swiss heritage, the company has a long tradition of doing business in and with Asia and is deeply rooted in communities and businesses across Asia Pacific.